Pipeline

Revolution Medicines has established a deep pipeline of programs targeting critical signaling nodes within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.

RMC-4630

RMC-4630, a potent and selective inhibitor of SHP2, is currently in a multi-cohort Phase 1/2 clinical program for a range of tumor types.

Mutant-selective RAS inhibitors

We believe our mutant-selective RAS inhibitors are the first potent, selective, cell-active inhibitors of the active, GTP-bound forms of RAS, or RAS(ON).

SOS1

We believe that inhibition of SOS1 may represent a viable approach for targeting RAS-driven tumors.

RMC-5552

RMC-5552, a potent and selective inhibitor of mTORC1, is designed to prevent inactivation of the tumor suppressive properties of the 4EBP1 protein.